Qube Research & Technologies LTD Compugen LTD Transaction History

Qube Research & Technologies LTD

$62.3 Billion
Q2 2024

A detailed history of Qube Research & Technologies LTD transactions in Compugen LTD stock. As of the latest transaction made, Qube Research & Technologies LTD holds 29,516 shares of CGEN stock, worth $52,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,516

Previous 54,936 46.27%

Holding current value

$52,538

Previous $141,000 65.25%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.68 - $2.52 $42,705 - $64,058	-25,420 Reduced 46.27%	29,516 $49,000
Q1 2024 May 14, 2024	BUY	$1.75 - $2.95 $95,602 - $161,158	54,630 Added 17852.94%	54,936 $141,000
Q4 2023 Feb 13, 2024	BUY	$0.53 - $2.0 $106 - $400	200 Added 188.68%	306 $0
Q3 2023 Nov 13, 2023	BUY	$0.88 - $1.31 $93 - $138	106 New	106 $0
Q2 2022 Aug 15, 2022	SELL	$1.57 - $3.33 $41,625 - $88,288	-26,513 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$2.76 - $4.64 $73,175 - $123,020	26,513 New	26,513 $85,000
Q3 2021 Nov 12, 2021	SELL	$5.8 - $8.02 $85,805 - $118,647	-14,794 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.87 - $9.16 $101,634 - $135,513	14,794 New	14,794 $122,000
Q1 2021 May 14, 2021	SELL	$7.67 - $13.77 $102,670 - $184,325	-13,386 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$12.07 - $17.95 $368,678 - $548,282	-30,545 Reduced 69.53%	13,386 $162,000
Q3 2020 Nov 12, 2020	BUY	$14.16 - $19.45 $38,302 - $52,612	2,705 Added 6.56%	43,931 $714,000
Q2 2020 Aug 14, 2020	BUY	$6.97 - $17.12 $194,985 - $478,932	27,975 Added 211.12%	41,226 $619,000
Q1 2020 May 15, 2020	BUY	$5.79 - $11.83 $76,723 - $156,759	13,251 New	13,251 $96,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.3M

Call Options Held

191K

Put Options Held

135K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $154M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Compugen LTD Transaction History